₩6.95 billion in Q3 revenue and continued operating profit
Vision as the First Mover in AI-driven Hyper-Personalized Organ Regeneration
Unprecedented balance of profitability and growth among listed biotech companies

ROKIT Healthcare (KOSDAQ: 376900, CEO Seokhwan You), a leading company specializing in AI-driven hyper-personalized organ regeneration, announced its preliminary results for the third quarter of 2025.

According to the disclosure, ROKIT Healthcare recorded consolidated revenue of ₩6.95 billion and an operating profit of ₩70 million in Q3, achieving a second consecutive quarter of operating profit since its KOSDAQ listing in May.

In particular, the third-quarter revenue represents an approximately 173% year-on-year increase, demonstrating the company’s steep growth trajectory. Cumulative sales for the first three quarters reached ₩16.6 billion, while the company’s stock price has more than tripled since its IPO.

ROKIT Healthcare has emerged as a rare case among biotech firms listed through the technology-special listing track to achieve profitability shortly after listing, establishing itself as a model for “post-listing, revenue-generating biotech.”

This performance reflects the success of its first-mover strategy that aligns with the global aging megatrend and expansion into advanced insurance markets, solidifying its position as a pioneer in the regenerative medicine industry. Market observers note that the company has presented a new precedent for sustainable, high-growth profitability in the biotech sector.

The company stated, “Our sales growth remains strong, and we are steadily meeting the business milestones presented in our securities registration statement at the time of listing.”

A ROKIT Healthcare spokesperson added, “This quarter’s results are significant as they validate both the growth potential and profitability we promised to the market during our IPO. We will continue to strive to contribute to the advancement of Korea’s biotech industry and to establish ourselves as a benchmark model for success among listed biotech companies.”